CORDIS
EU research results

CORDIS

English EN
Advancing a Precision Medicine Paradigm in metastatic Colorectal Cancer: Systems  based patient stratification solutions

Advancing a Precision Medicine Paradigm in metastatic Colorectal Cancer: Systems based patient stratification solutions

Objective

Colorectal cancer (CRC) is the third most common cancer in Europe with c. 420,000 cases and 150,000 related deaths in 2012. Of total CRC cases, it is estimated that approximately 50-55 % harbour RAS mutations. Current treatment for RAS mutant (mt) metastatic(m) CRC is primarily based on 5-fluoruracil based chemotherapy +/- bevacizumab. However, there are currently limited treatment options once cancers have become resistant. Moreover, while therapy optimization strategies in RAS wild-type CRC patients are feasible, targeted treatment of microsatellite stable (MSS) RAS mt disease is difficult and has not evolved significantly in recent years. COLOSSUS will deliver novel concepts for disease-mechanism based patient stratification in MSS RAS mt mCRC to address the need for stratified or personalised therapeutic interventions in this setting. The consortium will integrate multidimensional and longitudinal omics data to identify new MSS RAS mt specific subtypes with unique signalling dependences. We will harness the power of systems biomedicine, network analysis and computational modelling to identify new actionable pathways, biomarkers and targets across subtypes. These targets will be interrogated in state of the art pre-clinical patient derived xenograft studies. Newly described MSS RAS mt classifiers will be validated as novel patient stratification tools within the COLOSSUS trial. SME partners will develop clinically relevant and commercially viable assays for outcome prediction and stratification of MSS RAS mt patients based on novel classifiers. The impact of assays on CRC associated healthcare costs will further be assessed. Patient associations will be included and the proposal will consider regulatory aspects and commercialisation opportunities, in particular for participating SMEs. mCRC is a complex disease having high prevalence and high economic impact both within a European and global context.

Coordinator

ROYAL COLLEGE OF SURGEONS IN IRELAND

Address

Saint Stephen'S Green 123
2 Dublin

Ireland

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 1 345 143,69

Participants (13)

Sort alphabetically

Sort by EU Contribution

Expand all

FUNDACIO PRIVADA INSTITUT D'INVESTIGACIO ONCOLOGICA DE VALL-HEBRON

Spain

EU Contribution

€ 826 305,66

UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN

Ireland

EU Contribution

€ 351 091,16

THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL

United Kingdom

EU Contribution

€ 300 146,14

VIB

Belgium

EU Contribution

€ 601 518,66

RUPRECHT-KARLS-UNIVERSITAET HEIDELBERG

Germany

EU Contribution

€ 171 318,66

UNIVERSITA DEGLI STUDI DI TORINO

Italy

EU Contribution

€ 512 268,66

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE

France

EU Contribution

€ 159 518,66

IRISH CLINICAL ONCOLOGY RESEARCH GROUP LIMITED LBG

Ireland

EU Contribution

€ 233 654,91

OPTIMATA LTD

Israel

EU Contribution

€ 329 268,66

GENEXPLAIN GMBH

Germany

EU Contribution

€ 284 468,66

HALIODX

France

EU Contribution

€ 417 668,66

EPIGENOMICS AG

Germany

EU Contribution

€ 230 518,66

PINTAIL LTD

Ireland

EU Contribution

€ 233 468,66

Project information

Grant agreement ID: 754923

Status

Ongoing project

  • Start date

    1 January 2018

  • End date

    31 December 2022

Funded under:

H2020-EU.3.1.1.

  • Overall budget:

    € 5 996 359,50

  • EU contribution

    € 5 996 359,50

Coordinated by:

ROYAL COLLEGE OF SURGEONS IN IRELAND

Ireland